Mesoblast logo

Mesoblast(NASDAQ) MESO

Market Cap$1.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)+74%
5 Year+21%
1 Year-21%
1 Month-21%
Premium Feature
Moneyball Superscore
65/100
$13.62
-4.22%
-0.60Today
After hours$13.93+$0.31 (+2.28%)
Mesoblast last closing stock price
MetricPriceDate
Last closeUSD 13.612026-10-06
Mesoblast stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.47%USD 14.872026-09-29
1 month-21.42%USD 17.322026-09-04
3 month-8.04%USD 14.802026-07-08
Year to date-24.56%USD 18.042025-12-31
1 year-21.42%USD 17.322025-10-06
3 year+476.69%USD 2.362023-10-06
5 year+20.66%USD 11.282021-10-07
Since inception+74.44%USD 8.152005-12-15

Mesoblast Financials at a Glance

Market Cap

$1.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$120.79M

Net Income (TTM)

-$57.50M

EPS (TTM)

-$0.45

P/E Ratio

-30.55

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$13.62

Volume

404,695.935

Open

$13.90

Previous Close

$13.61

Daily Range

$13.58 - $13.90

52-Week Range

$13.05 - $21.50

Estimated Earnings Date

Mar 4, 2027

MESO News

Physician going over results with patient

Why Shares of Mesoblast Are Down Monday

James HalleyAug 7, 2023
guardant

Why Shares of Mesoblast Are Plunging Friday

James HalleyAug 4, 2023
GettyImages-1200706447

Why Mesoblast Limited Stock Is Jumping Today

Prosper Junior BakinyApr 30, 2021
GettyImages-871536340

Why Mesoblast Limited Is Rising Today

Prosper Junior BakinyFeb 11, 2021
GettyImages-1089374276

Why Mesoblast Stock Skyrocketed Today

Prosper Junior BakinyJan 11, 2021
market crash share prices fall

Why Mesoblast Stock Plummeted on Friday

Jon QuastDec 18, 2020
Heart monitoring ECG

Why Mesoblast Stock Is Tanking Today

Keith SpeightsDec 15, 2020
Scientist in lab looking through microscope

Why Mesoblast Stock Is Blasting Off Today

Keith SpeightsNov 20, 2020
Page 1

MESO: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mesoblast

Mesoblast Limited is a biopharmaceutical firm focused on developing and commercializing allogeneic cell-based therapies. The company operates globally, addressing various medical conditions through its proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells.

Products and Services
  • Remestemcel-L for severe, steroid-refractory acute graft versus host disease
  • Rexlemestrocel-L targeting advanced chronic heart failure
  • MPC-06-ID for chronic low back pain from degenerative disc disease
Growth Outlook
  • Several product candidates are in Phase III clinical trials, indicating strong pipeline potential
  • Strategic partnerships enhance market reach and distribution capabilities
  • Focus on addressing unmet medical needs in diverse therapeutic areas
Financial Highlights
  • Recent quarterly revenue of $34.5 million shows growth compared to previous quarters
  • Cash and cash equivalents stand at $102.9 million, providing operational stability
  • Gross profit margin of 78.3% reflects strong product demand and pricing power
Mesoblast Limited is positioned in the biotechnology sector, with a focus on innovative therapies that address significant health challenges. The company's ongoing clinical trials and strategic partnerships are critical for its growth trajectory. Recent financial performance indicates a solid revenue stream and a healthy cash position, which are essential for funding further research and development. The emphasis on regenerative medicine and cell-based therapies aligns with current trends in healthcare, making Mesoblast a noteworthy entity in the biopharmaceutical landscape.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

108

CEO

Silviu Itescu, PhD

Website

www.mesoblast.com

Headquarters

Melbourne, VIC 3000, AU

MESO Financials

Key Financial Metrics (TTM)

Gross Margin

78.30%

Operating Margin

-96.11%

Net Income Margin

-46.79%

Return on Equity

-10.06%

Return on Capital

-7.40%

Return on Assets

-7.44%

Earnings Yield

-3.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

129.85M

Volume

404.70K

Avg. Volume

236.37K

Financials (TTM)

Gross Profit

$96.22M

Operating Income

-$118.11M

EBITDA

-$45.01M

Operating Cash Flow

-$41.32M

Capital Expenditure

-$1.04M

Free Cash Flow

-$42.36M

Cash & ST Invst.

$102.91M

Total Debt

$127.33M

Mesoblast Performance Analysis

Mesoblast annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 7,467,164-26.9%
20242024-06-30USD 5,923,635-20.7%
20252025-06-30USD 17,168,763189.8%
20262026-06-30USD 120,787,178603.5%
Mesoblast sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30265.6%
Q22025-12-31N/A
Q32026-03-3134.2%
Q42026-06-301.6%
Mesoblast annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -1.05-21.6%
20242024-06-30USD -0.89-14.4%
20252025-06-30USD -0.84-5.6%
20262026-06-30USD -0.45-47.2%
Mesoblast sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-3027.2%
Q22025-12-31N/A
Q32026-03-3156.8%
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$34.99M

+398.4%

Gross Profit

$49.32M

+404.0%

Gross Margin

1.41%

N/A

Market Cap

$1.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$16.36M

N/A

Employees

108

N/A

Net Income

-$8.67M

+68.0%

EBITDA

-$9.97M

+49.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$102.91M

-36.1%

Total Debt

$127.33M

-0.6%

Accounts Receivable

$57.08M

+283.9%

Inventory

$28.11M

+26.4%

Long Term Debt

$113.71M

+59.4%

Short Term Debt

$13.63M

-76.0%

Return on Assets

-7.44%

N/A

Return on Invested Capital

-17.07%

N/A

Free Cash Flow

-$6.95M

+53.5%

Operating Cash Flow

-$6.74M

+54.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAPRCapricor Therapeutics, Inc.
$7.75-0.39%
FATEFate Therapeutics, Inc.
$2.29-5.76%
LEGNLegend Biotech Corporation
$18.72-0.29%
CELUCelularity Inc.
$1.58-7.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$171.92+0.48%
INTCIntel
$112.50-3.18%
NVDANvidia
$239.24+0.14%
NUNu Holdings
$15.66+3.16%

Questions About MESO

What is the current price of Mesoblast?

Mesoblast is trading at $13.61 per share.

What is the 52-week range for Mesoblast?

Over the past 52 weeks, Mesoblast has traded between $13.05 and $21.50.

How much debt does Mesoblast have?

As of the most recent reporting period, Mesoblast reported total debt of $127.33M.

How much cash does Mesoblast have on hand?

Mesoblast reported $102.91M in cash and cash equivalents in its most recent financial results.

What is Mesoblast’s dividend yield?

Mesoblast does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services